The stock of GlycoMimetics Inc (GLYC) has gone down by -16.46% for the week, with a -23.03% drop in the past month and a 77.46% rise in the past quarter. The volatility ratio for the week is 10.51%, and the volatility levels for the past 30 days are 11.58% for GLYC. The simple moving average for the last 20 days is -17.06% for GLYC stock, with a simple moving average of -64.63% for the last 200 days.
Is It Worth Investing in GlycoMimetics Inc (NASDAQ: GLYC) Right Now?
The 36-month beta value for GLYC is also noteworthy at 1.78. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GLYC is 57.07M, and at present, short sellers hold a 6.66% of that float. The average trading volume of GLYC on December 06, 2024 was 19.63M shares.
GLYC) stock’s latest price update
GlycoMimetics Inc (NASDAQ: GLYC)’s stock price has increased by 1.51 compared to its previous closing price of 0.29. However, the company has seen a -16.46% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-12 that Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ — Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.
Analysts’ Opinion of GLYC
CapitalOne, on the other hand, stated in their research note that they expect to see GLYC reach a price target of $12. The rating they have provided for GLYC stocks is “Overweight” according to the report published on December 22nd, 2023.
Jefferies gave a rating of “Buy” to GLYC, setting the target price at $4 in the report published on November 12th of the previous year.
GLYC Trading at 4.73% from the 50-Day Moving Average
After a stumble in the market that brought GLYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.79% of loss for the given period.
Volatility was left at 11.58%, however, over the last 30 days, the volatility rate increased by 10.51%, as shares sank -31.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +68.68% upper at present.
During the last 5 trading sessions, GLYC fell by -17.09%, which changed the moving average for the period of 200-days by -90.18% in comparison to the 20-day moving average, which settled at $0.3493. In addition, GlycoMimetics Inc saw -87.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLYC starting from Invus Public Equities, L.P., who sale 260,873 shares at the price of $0.19 back on Aug 08 ’24. After this action, Invus Public Equities, L.P. now owns 6,317,565 shares of GlycoMimetics Inc, valued at $50,009 using the latest closing price.
Invus Public Equities, L.P., the 10% Owner of GlycoMimetics Inc, sale 61,488 shares at $0.18 during a trade that took place back on Aug 07 ’24, which means that Invus Public Equities, L.P. is holding 6,578,438 shares at $11,197 based on the most recent closing price.
Stock Fundamentals for GLYC
Current profitability levels for the company are sitting at:
- -4229.75 for the present operating margin
- -4.03 for the gross margin
The net margin for GlycoMimetics Inc stands at -3973.54. The total capital return value is set at -0.0. Equity return is now at value -137.20, with -115.34 for asset returns.
Based on GlycoMimetics Inc (GLYC), the company’s capital structure generated 0.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13. The debt to equity ratio resting at 23.04. The interest coverage ratio of the stock is -72.68.
Currently, EBITDA for the company is -39.12 million with net debt to EBITDA at -6.75. When we switch over and look at the enterprise to sales, we see a ratio of 26619.67. The receivables turnover for the company is 0.2for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In summary, GlycoMimetics Inc (GLYC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
